Sulfated oligosaccharide-based inhibitors of tumour metastasis

Parish, C R; Freeman, Craig; Cowden, B

doi:10.1097/00008390-199706001-00186

Cited by 17 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12-17 2 It has been demonstrated in numerous studies that heparin can reduce metastasis of carcinoma 3 cells in animal models of experimental metastasis and benefit human malignant desease. 21-24 The 4 underlying mechanism, which is not clear entirely, may be releated with the ability of heparin to 5 interact with multiple molecules, such as heparinase, P-and L-selectins and growth factors. 13 6…”

Section: Advantages Of Using Heparin In Cancer Nanotechnolegy 20mentioning

confidence: 99%

Advanced Nanocarriers Based on Heparin and Its Derivatives for Cancer Management

et al. 2015

View full text Add to dashboard Cite

To obtain a satisfying anticancer effect, rationally designed nanocarriers are intensively studied. In this field, heparin and its derivatives have been widely attempted recently as potential component of nanocarriers due to their unique biological and physiochemical features, especially the anticancer activity. This review focuses on state-of-the-art nanocarriers with heparin/heparin derivatives as backbone or coating material. At the beginning, the unique advantages of heparin used in cancer nanotechnology are discussed. After that, different strategies of heparin chemical modification are reviewed, laying the foundation of developing various nanocarriers. Then a systematic summary of diverse nanoparticles with heparin as component is exhibited, involving heparin-drug conjugate, polymeric nanoparticles, nanogels, polyelectrolyte complex nanoparticles, and heparin-coated organic and inorganic nanoparticles. The application of these nanoparticles in various novel cancer therapy (containing targeted therapy, magnetic therapy, photodynamic therapy, and gene therapy) will be highlighted. Finally, future challenges and opportunities of heparin-based biomaterials in cancer nanotechnology are discussed.

show abstract

Section: Advantages Of Using Heparin In Cancer Nanotechnolegy 20mentioning

confidence: 99%

Advanced Nanocarriers Based on Heparin and Its Derivatives for Cancer Management

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The latter include prostate, bladder, pancreas, colon, breast, ovarian, hepatocellular, gastric, and oral squamous cell carcinomas, as well as melanoma (Hulett et al, 1999;Vlodavsky et al, 1999;Friedmann et al, 2000;McKenzie et al, 2000;Parish et al, 2001). Overexpression of the heparanase cDNA in low-metastatic tumor cells conferred a high metastatic potential (Vlodavsky et al, 1999), and treatment with heparanase inhibitors (PI-88) or antisense constructs markedly reduced the incidence of metastasis in experimental animals (Nakajima et al, 1988;Parish et al, 1999Parish et al, , 2001Uno et al, 2001) (reviewed in Parish et al, 2001). Furthermore, elevated levels of heparanase were detected in the serum of animals bearing metastatic tumors and cancer patients (Nakajima et al, 1988).…”

Section: Heparanase and Heparan Sulfate Proteoglycansmentioning

confidence: 99%

Axis of evil: molecular mechanisms of cancer metastasis

2003

View full text Add to dashboard Cite

Although the genetic basis of tumorigenesis may vary greatly between different cancer types, the cellular and molecular steps required for metastasis are similar for all cancer cells. Not surprisingly, the molecular mechanisms that propel invasive growth and metastasis are also found in embryonic development, and to a less perpetual extent, in adult tissue repair processes. It is increasingly apparent that the stromal microenvironment, in which neoplastic cells develop, profoundly influences many steps of cancer progression, including the ability of tumor cells to metastasize. In carcinomas, the influences of the microenvironment are mediated, in large part, by bidirectional interactions (adhesion, survival, proteolysis, migration, immune escape mechanisms lymph-/angiogenesis, and homing on target organs) between epithelial tumor cells and neighboring stromal cells, such as fibroblasts as well as endothelial and immune cells. In this review, we summarize recent advances in understanding the molecular mechanisms that govern this frequently lethal metastatic progression along an axis from primary tumor to regional lymph nodes to distant organ sites. Affected proteins include growth factor signaling molecules, chemokines, cell-cell adhesion molecules (cadherins, integrins) as well as extracellular proteases (matrix metalloproteinases). We then discuss promising new therapeutic approaches targeting the microenvironment. We note, however, that there is still too little knowledge of how the many events are coordinated and integrated by the cancer cell, with conspiratorial help by the stromal component of the host. Before drug development can proceed with a legitimate chance of success, significant gaps in basic knowledge need to be filled.

show abstract

“…The antimetastatic effects of heparanase inhibitors have been reported in vitro and in vivo (8,40,42,47,48). In addition, our findings suggest that inhibitors of the formation of the disulfide bond may be developed into effective therapeutic agents for the treatment of heparanaseoverexpressing cancers.…”

Section: Discussionmentioning

confidence: 56%

Involvement of Disulfide Bond Formation in the Activation of Heparanase

Simizu¹,

Suzuki

Muroi³

et al. 2007

Cancer Research

View full text Add to dashboard Cite

Heparanase is overexpressed in many solid tumor cells and is capable of specifically cleaving heparan sulfate, and this activity is associated with the metastatic potential of tumor cells; however, the activation mechanism of heparanase has remained unknown. In this study, we investigated the link between disulfide bond formation and the activation of heparanase in human tumor cells. Mass spectrometry analysis of heparanase purified from a conditioned medium of human fibrosarcoma cells revealed two disulfide bonds, Cys

show abstract

Sulfated oligosaccharide-based inhibitors of tumour metastasis

Cited by 17 publications

References 0 publications

Advanced Nanocarriers Based on Heparin and Its Derivatives for Cancer Management

Advanced Nanocarriers Based on Heparin and Its Derivatives for Cancer Management

Axis of evil: molecular mechanisms of cancer metastasis

Involvement of Disulfide Bond Formation in the Activation of Heparanase

Contact Info

Product

Resources

About